Motivation to succeed, mission to reduce disability

Neuronsweb-140x94BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorders.  Leveraging 20 years of pioneering research in diseases involving Rho/ROCK signaling,  BioAxone’s lead drug candidate is an orally-available ROCK2 inhibitor restoring endothelial cell barriers in cavernous angioma (CA) and stroke.